Hypercholesterolemia and LDL apheresis

International Journal of Artificial Organs

Volumn 28, Issue 10, 2005, Pages 1025-1031

  Morelli, Federico ^a   Carlier, P ^a   Giannini, G ^a   De Luigi, M C ^a   Dejana, A ^a   Ruzzenenti, M R ^a   Valbonesi, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Coronary angiographic trials; DALI; Dextran sulphate absorption; Familial hypercholesterolemia; HELP; Immunoadsorption; Lipidfiltration

Indexed keywords

CARDIOLOGY; DEXTRAN; HEART; LIPOPROTEINS; SULFUR COMPOUNDS;

CORONARY ANGIOGRAPHIC TRIAL; DEXTRAN SULPHATE; DEXTRAN SULPHATE ABSORPTION; DIRECT ADSORPTION OF LIPOPROTEIN USING HEMOPERFUSION; FAMILIAL HYPERCHOLESTEROLEMIA; HEMOPERFUSION; HEPARIN EXTRACORPOREAL LDL PRECIPITATION SYSTEM; IMMUNOADSORPTION; LIPIDFILTRATION; PRECIPITATION SYSTEMS; SULPHATE ABSORPTION;

DISEASES;

ANTILIPEMIC AGENT; CELLULOSE; DEXTRAN SULFATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADSORPTION; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; EXTRACORPOREAL CIRCULATION; FAMILIAL HYPERCHOLESTEROLEMIA; FILTRATION; HEMOFILTRATION; HEMOPERFUSION; HUMAN; IMMUNOADSORPTION; ISCHEMIC HEART DISEASE; METHODOLOGY; PLASMAPHERESIS; PRECIPITATION; TREATMENT INDICATION;

EID: 29244455281     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880502801010     Document Type: Article

References (73)

1. McGill HC Jr (Ed.). Introduction to the geographic pathology of atherosclerosis. Lab Invest 1968; 18: 463-653.
2. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow up from the Framingham Study. JAMA 1987; 257: 2176-80.
3. Keys A. Seven Countries. A multivariate analysis of death and coronary heart disease. Cambridge, MA: Harvard University Press; 1980.
4. Stamler J, Wentworth D, Neaton JD for the MRFIT Research Group. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-28.
5. Steinberg D, Parthasarathy C, Carew TE, Khoo JC, Witzum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
6. Toshima S, Hasegawa A, Kurabayashi M, et al. Circulating oxidized low-density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20: 2243-7.
7. Vasankari T, Ahotupa M, Toikka J, et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: Lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001; 155: 403-12.
8. Rosenson RS. Statins in atherosclerosis: Lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004; 173: 1-12.
9. Young CE, Karas RH, Kuvin JT. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev 2004; 12: 107-19.
10. Scandinavian Simvastatin Survival Study group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
11. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-7.
12. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
15. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP), expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
16. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994; 89: 1333-445.
17. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55-68.
18. Hudgins LC, Gordon BR, Parker TS, et al. LDL apheresis: An effective and safe treatment for refractory hypercholesterolemia. Cardiovasc Drug Rev 2002; 20: 271-80.
19. Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol 1994; 74: 1109-12.
20. Bosch T. Lipid apheresis: From a heroic treatment to routine clinical practice. Artif Organs 1996; 20: 414-9.
21. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990; 264: 3007-12.
22. Tatami R, Inoue N, Itoh H, et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: A multicenter study. The LARS Investigators. Atherosclerosis 1992; 95: 1-13.
23. Nishimura S, Sekiguchi M, Kano T, et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999; 144: 409-17.
24. Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolemia Regression Study: A randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345: 811-6.
25. Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826-35.
26. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): A prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81.
27. Thompson GR. LDL apheresis. Atherosclerosis 2003; 167: 1-13.
28. Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82: 1489-95.
29. Matsuzaki M, Hiramori K, Imaizumi T, et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: The low density lipoprotein-apheresis coronary morphology and reserve trial (LACMART). J Am Coll Cardiol 2002; 40: 220-7.
30. Hoffmann U, Derfler K, Haas M, et al. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am J Cardiol 2003; 91: 461-4.
31. Schamberger BM, Geiss HC, Ritter MM, et al. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res 2000; 41: 727-33.
32. Ohmura H, Mokuno H, Sawano M, et al. Lipid compositional differences of small, dense low-density lipoprotein particles influence its oxidative susceptibility: Possible implication of increased risk of coronary artery disease in subjects with phenotype B. Metabolism 2002; 51: 1081-7.
33. Tamai O, Matsuoka. H, Itabe H, et al. Single LDL-apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
34. Jaeger BR. Evidence for maximal treatment of atherosclerosis: Drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. Ther Apher 2001; 5: 207-11.
35. Suckfüll M; Hearing Loss Study Group. Fibrinogen and LDL-apheresis in treatment of sudden hearing loss: A randomised multicenter study. Lancet 2002; 360: 1811-7.
36. Klingel R, Fassbender C, Fisher I, et al. Rheopheresis for age related macular degeneration: A novel indication for therapeutic apheresis in ophtalmology. Ther Apher 2002; 6: 271-81.
37. Knisel W, Pfohl M, Muller M, et al. Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low density lipoproteins. Clin Investig 1994; 72: 660-8.
38. Schaumann D, Welch-Wichary M, Voss A, et al. Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 1996; 26: 1033-8.
39. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. LDL hemoperfusion - a new procedure for LDL apheresis: First clinical application of an LDL adsorber compatible with human whole blood. Artif Organs 1997; 21: 977-82.
40. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: A long-term evaluation. Ther Apher 1999; 3: 203-8.
41. Schmaldienst S, Banyai S, Stulnig TM, et al.Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 2000; 151: 493-9.
42. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 2000; 4: 382-5.
43. Julius U, Siegert G, Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 2000; 23: 199-206.
44. Bambauer R. Low-density lipoprotein apheresis: Clinical results with different methods. Artif Organs 2002; 26: 133-9.
45. Klingel R, Mausfeld P, Fassbender C, Göhlen B. Lipidfiltration - safe and effective methodology to perform lipid-apheresis. Transfus Apher Sci 2004; 30: 245-54.
46. Cashin-Hemphill L, Noone M, Abbott JF, et al. Low density lipoprotein apheresis therapy during pregnancy. Am J Cardiol 2000; 86: 1160, A10.
47. Klingel R, Göhlen B, Schwarting A, et al. Differential indication of lipoprotein apheresis during pregnacy. Ther Apher Dial 2003; 7: 359-64.
48. Olbricht CJ, Schaumann D, Fisher D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet 1992; 340: 908-9.
49. Bosch T, Lennertz A, Schmidt B, et al. DALI apheresis in hyperlipidemic patients: Biocompatibility, efficacy, and hemodynamics during LDL apheresis. Artif Organs 2000; 24: 81-90.
50. DeGienne JL, Toutaine R, Maunand B, et al. Forme homozygous cutaneo-tendineuses de xanthomatose hypercholesterolemique dans une observation familiale exemplaire. Essai de plasmapherese a titre de traitment heroique. Bull Mem Soc Med Hop Paris 1967; 118: 1377-402.
51. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975; 1: 1208-11.
52. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolemia: Removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1976; 1: 1261-5.
53. Brown MS, Goldstein JL. Familial hypercholesterolemia: Defective binding of lipoprotein to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutarylcoenzyme A reductase activity. Proc Natl Acad Sci USA 1974; 71: 788-92.
54. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976; 29: 1346-8.
55. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2: 1005-7.
56. Armstrong VW, Windisch M, Wieland H, et al. Selective continous extracorporal elimination of low-density lipoproteins with heparin at acidic pH. Trans Am Soc Artif Intern Organs 1983; 29: 323-8.
57. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985; 5: 613-22.
58. Mabuchi H, Michishita I, Takeda M, et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated regenerating unit (LDL continous apheresis). Atherosclerosis 1987; 68: 19-25.
59. Saal SD, Parker TS, Gordon BR, et al. Removal of low density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 1986; 80: 583-9.
60. Pokrovsky SN, Adamova IY, Benevolenskaya GF. Immunosorbents for LDL apheresis. Biomater Artif Cells Artif Organs 1990; 18: 623-8.
61. Kitano Y, Thompson GR. Role of LDL apheresis in management of hypercholesterolemia. Transfus Sci 1993; 14: 1269-80.
62. Zwiener RJ, Uauy R, Petruska ML, Huet BA. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia. J Pediatr 1995; 126: 728-35.
63. Stefanutti C, Vivenzio A, Colombo C, et al. Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. Int J Artif Organs 1995; 18: 103-10.
64. Zschocke J, Schaefer JR. Homozygous familial hypercholesterolaemia in identical twins. Lancet 2003; 361: 1641.
65. Thomas HP, Vogt A, Wilund KR, et al. Autosomal recessive hypercholesterolemia in three sisters with phenotypic homozygous familial hypercholesterolemia: Diagnostic and therapeutic procedures. Ther Apher Dial 2004; 8: 275-80.
66. Bilheimer DW, Goldstein JL, Grundy SM, et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311: 1658-64.
67. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6: 335-41.
68. Susca M. Heparin-induced extracorporeal low-density lipoprotein precipitation futura, a new modification of HELP apheiresis: Technique and clinical results. Ther Apher 2001; 5: 387-93.
69. Bosch T, Lennertz A, Samtleben W. High-efficiency DALI apheresis using 1,250 mL adsorbers in a hyperchlolesterolemic obese patient: A case report. Ther Apher 2001; 5: 358-63.
70. Otto C, Kern P, Bambauer R, et al. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003; 27: 1116-22.
71. Klinge R, Fassbender T, Fassbender C, Göhlen B. From membrane differential filtration to lipidfiltration: Technological progress in low-density lipoprotein apheresis. Ther Apher Dial 2003; 7: 350-8.
72. Barter PJ. Coronary plaque regression: Role of low density lipoprotein-apheresis. J Am Coll Cardiol 2002; 40: 228-30.
73. Koga N, Watanabe K, Kurashige Y, et al. Long-term effects of LDL apheresis on carorotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med 1999; 246: 35-43.